KR890003740A - 약제학적으로 유용한 부스피론의 다형성 변형 - Google Patents

약제학적으로 유용한 부스피론의 다형성 변형 Download PDF

Info

Publication number
KR890003740A
KR890003740A KR1019880010978A KR880010978A KR890003740A KR 890003740 A KR890003740 A KR 890003740A KR 1019880010978 A KR1019880010978 A KR 1019880010978A KR 880010978 A KR880010978 A KR 880010978A KR 890003740 A KR890003740 A KR 890003740A
Authority
KR
South Korea
Prior art keywords
busyron
pharmaceutically useful
polymorphic variation
useful polymorphic
hydrochloride
Prior art date
Application number
KR1019880010978A
Other languages
English (en)
Other versions
KR970011297B1 (ko
Inventor
씨. 심스 잭
Original Assignee
이삭 야코브스키
브리스톨 마이어즈 컴패니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22225222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890003740(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 이삭 야코브스키, 브리스톨 마이어즈 컴패니 filed Critical 이삭 야코브스키
Publication of KR890003740A publication Critical patent/KR890003740A/ko
Application granted granted Critical
Publication of KR970011297B1 publication Critical patent/KR970011297B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Body Structure For Vehicles (AREA)

Abstract

내용 없음

Description

약제학적으로 유용한 부스피론의 다형성 변형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 융점이 약 188°C임을 특징으로 하는 부스피론 히드로클로라이드의 저용융 다형성 결정체.
  2. 제1항의 저용융 부스피론 히드로클로라이드 다형체를 치료유효량 투여하는 것을 특징으로 하는 환자의 불안을 치료하기 위한 방법.
  3. 제1항의 저용융 부스피론 히드로클로라이드 다형체 및 운반체를 포함하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880010978A 1987-08-28 1988-08-27 부스피론 다결정체 및 이를 함유하는 약학적 조성물 KR970011297B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US090984 1987-08-28
US07/090,984 US5015646A (en) 1987-08-28 1987-08-28 Pharmaceutically useful polymorphic modification of buspirone

Publications (2)

Publication Number Publication Date
KR890003740A true KR890003740A (ko) 1989-04-17
KR970011297B1 KR970011297B1 (ko) 1997-07-09

Family

ID=22225222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880010978A KR970011297B1 (ko) 1987-08-28 1988-08-27 부스피론 다결정체 및 이를 함유하는 약학적 조성물

Country Status (22)

Country Link
US (1) US5015646A (ko)
EP (1) EP0304941B1 (ko)
JP (1) JP2716740B2 (ko)
KR (1) KR970011297B1 (ko)
AT (1) ATE101147T1 (ko)
AU (1) AU618549B2 (ko)
CY (1) CY1785A (ko)
DE (1) DE3887598T2 (ko)
DK (1) DK170821B1 (ko)
ES (1) ES2061576T3 (ko)
FI (1) FI883961A (ko)
HK (1) HK74494A (ko)
HU (1) HU201322B (ko)
IE (1) IE63071B1 (ko)
IL (1) IL87468A (ko)
MY (1) MY104061A (ko)
NO (1) NO883805D0 (ko)
NZ (1) NZ225896A (ko)
OA (1) OA08908A (ko)
PT (1) PT88356B (ko)
YU (1) YU46962B (ko)
ZA (1) ZA886082B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
PT1956014T (pt) 1998-06-19 2019-04-24 Teijin Pharma Ltd Polimorfos de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil- 5-tiazolecarboxílico e método para a sua produção
US6465255B1 (en) * 1999-01-29 2002-10-15 The Regents Of The University Of California Method for identifying and probing phase transitions in materials
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4351939A (en) * 1980-10-16 1982-09-28 Mead Johnson & Company Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치

Also Published As

Publication number Publication date
HU201322B (en) 1990-10-28
ZA886082B (en) 1989-04-26
NO883805D0 (no) 1988-08-25
DE3887598D1 (de) 1994-03-17
DK170821B1 (da) 1996-01-29
EP0304941A1 (en) 1989-03-01
US5015646A (en) 1991-05-14
ATE101147T1 (de) 1994-02-15
KR970011297B1 (ko) 1997-07-09
AU618549B2 (en) 1992-01-02
FI883961A0 (fi) 1988-08-26
PT88356A (pt) 1989-06-30
EP0304941B1 (en) 1994-02-02
YU46962B (sh) 1994-09-09
DE3887598T2 (de) 1994-05-19
PT88356B (pt) 1995-03-31
FI883961A (fi) 1989-03-01
DK478788D0 (da) 1988-08-26
JPS6471816A (en) 1989-03-16
ES2061576T3 (es) 1994-12-16
HUT47564A (en) 1989-03-28
NZ225896A (en) 1991-04-26
HK74494A (en) 1994-08-05
JP2716740B2 (ja) 1998-02-18
AU2107688A (en) 1989-03-02
YU161688A (en) 1990-10-31
IL87468A (en) 1992-12-01
CY1785A (en) 1995-10-20
IE882528L (en) 1989-02-28
OA08908A (en) 1989-10-31
DK478788A (da) 1989-03-01
IL87468A0 (en) 1989-01-31
IE63071B1 (en) 1995-03-22
MY104061A (en) 1993-11-30

Similar Documents

Publication Publication Date Title
KR890003740A (ko) 약제학적으로 유용한 부스피론의 다형성 변형
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI953467A0 (fi) Aminohappojohdannaisia, näitä yhdisteitä sisältävät lääkeaineet ja menetelmä niiden valmistamiseksi
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ES2102367T3 (es) Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
BE777689A (fr) Nouveaux derives de l'imidazoline, compositions therapeutiques les contenant ainsi que le procede de preparation de ces derives et de ces compositions
IT1188908B (it) Composti eterociclici dotati di proprieta' farmacologiche e procedimento per la loro preparazione
GEP20022636B (en) 4-[5-Methyl-3-Phenylisoxazol-4-Yl] Benzenesulfonamide, Its Crystal Structure B, Pharmaceutical Composition Containing The Same, Methods For Treatment Or Prophylaxis Of Disorders Caused By Cyclooxygen-2
IT8621358A0 (it) Composizione farmaceutica adattivita' analgesica.
FR2597870B1 (fr) 0,3,2-oxazaphospholidines, leur emploi pour stabiliser des matieres organiques et compositions de matieres organiques contenant ces substances
IT7849358A0 (it) Procedimento per la cura farmacologica dell'abitudine alla droga con alfa-metil-para-tirosina
FI94354C (fi) Menetelmä farmaseuttisesti aktiivisten peptidien valmistamiseksi
DE3686022D1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
FR2621587B1 (fr) Derives du dimethyl-2,2 chromene, procede pour leur preparation et composition pharmaceutiques les contenant
KR910021361A (ko) 항궤양 물질
KR900014382A (ko) (s)-7-(3-아미노-1-피롤리디닐)-1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-나프티리딘-3-카르복실산
MX9203140A (es) Derivados de 4 fenil-4(n-(fenil)amido)-piperidina y las composiciones farmaceuticas, asi como el metodo aplicado para tales compuestos.
IT1206130B (it) Composti per abbassare i livelli dei lipidi.
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
FR2315921A1 (fr) Thioindoles substitues sur l'atome de soufre et eventuellement sur le noyau indole, procede de preparation de ceux-ci, et agents therapeutiques en comportant application
IT8349538A0 (it) Esteri di derivati 3-(3-sostituitoammino-2-idrossi-propossi)-4-sostituito-1,2,5-tiadiazolici utili come agenti bloccanti beta-adrenergici eper il trattamento del glaucoma
BE860162A (fr) Derives actifs de l'uree leur procede de preparation ainsi que les compositions therapeutiques les contenant
KR880004810A (ko) 소화성 궤양 치료제
NO179838C (no) Fremgangsmåte for fremstilling av S-(-)-3-morfolino-4-(3-tert-butylamino-2-hydroksypropoksy)-1,2,5-tiadiazol-hemihydrat
KR880012226A (ko) 외 용 제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031205

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee